Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 17, 2022

Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations

Diabetes Care

 

Additional Info

Diabetes Care
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials
Diabetes Care 2022 Apr 01;45(4)1007-1012, H Tang, SE Kimmel, SM Smith, K Cusi, W Shi, M Gurka, AG Winterstein, J Guo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading